RxDoctor Payments Data

Richard Arakaki

Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1093702656

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Bayer accounts for 60.0% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $3,382 and has fallen 95.4% since, to $154 in 2025.

$5,724in general payments, 2019–2025

Across 73 payments — averaging $78.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$3K
  • Viiv Healthcare Company$474
  • Novo Nordisk$411
  • Tandem Diabetes Care, Inc.$170
  • Gilead$169
  • AbbVie$162
  • plus $902 from 17 others
$14,644in research payments, 2019–2025

Across 1 payment — averaging $14,644 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$15K

What the payments were for

  • Consulting fees$3,04553%
  • Food & beverage$2,61546%
  • Education$651%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,724 in reported general payments places this provider in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide29$27,684
OzempicSemaglutide14$24,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$32$27,68429 claims
Novo NordiskOzempic$411$24,44914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

Other endocrinology, diabetes & metabolism in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →